Chakma Justin 4
4 · ARS Pharmaceuticals, Inc. · Filed Dec 13, 2024
Insider Transaction Report
Form 4
Chakma Justin
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2024-12-12$0.84/sh+117,333$98,560→ 253,713 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-13−27,272→ 55,461 totalExercise: $1.44Exp: 2031-12-13→ Common Stock (27,272 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-12−117,333→ 119,047 totalExercise: $0.84Exp: 2029-07-04→ Common Stock (117,333 underlying) - Sale
Common Stock
2024-12-12$12.27/sh−117,333$1,439,124→ 136,380 total - Exercise/Conversion
Common Stock
2024-12-13$1.44/sh+27,272$39,272→ 163,652 total - Sale
Common Stock
2024-12-13$12.06/sh−27,272$328,969→ 136,380 total
Footnotes (3)
- [F1]The weighted average sale price for the transaction reported was $12.2653, and the range of prices were between $11.83 and $12.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F2]The weighted average sale price for the transaction reported was $12.0625, and the range of prices were between $11.83 and $12.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]Immediately exercisable.